(Q44368433)

English

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

scientific article published in March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

0 references

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

hypercholesterolemia

0 references

author name string

James W Blasetto

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Evan A Stein

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

W Virgil Brown

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Rohini Chitra

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ali Raza

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

5A

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

3C-10C; discussion 10C

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Low-density lipoproteins and risk for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

The US National Cholesterol Education Program. Adult treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900003-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9149(03)00003-1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

release_jyxfcpw6f5bdbfmric6n5ubu7y

1 reference

https://api.fatcat.wiki/v0/release/jyxfcpw6f5bdbfmric6n5ubu7y

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44368433&oldid=2020178174"